A forced marriage of IL-2 and PD-1 antibody nurtures tumor-infiltrating T cells.
A forced marriage of IL-2 and PD-1 antibody nurtures tumor-infiltrating T cells.
复制标题
DOI：
10.1172/jci156628
复制
发表时间：
2022-02-01
期刊：
影响因子：
--
通讯作者：
Zou W
中科院分区：
文献类型：
--
作者：
Holcomb EA;Zou W
IL-2是一种多效性细胞因子。在本期JCI中，Ren等人报道了与抗PD-1（PD-1-laIL-2）配对的低亲和力IL-2的开发，其重新激活肿瘤内的CD 8 + T细胞，但不激活CD 4 + Treg细胞。PD-1-IaIL-2治疗与抗PD-L1疗法协同作用以克服荷瘤小鼠中肿瘤对免疫检查点阻断（ICB）的抗性。PD-1-laIL-2治疗后再激发的肿瘤的排斥证明了有效T细胞记忆应答的建立。此外，PD-1-IaIL-2治疗没有表现出明显的毒性。这些发现表明PD-1-IaIL-2疗法在治疗癌症患者中的潜力。
IL-2 is a pleiotropic cytokine. In this issue of the JCI, Ren et al. report on the development of a low-affinity IL-2 paired with anti–PD-1 (PD-1–laIL-2) that reactivates intratumoral CD8+ T cells, but not CD4+ Treg cells. PD-1–laIL-2 treatment synergized with anti–PD-L1 therapy to overcome tumor resistance to immune checkpoint blockade (ICB) in tumor-bearing mice. Rejection of rechallenged tumors following PD-1–laIL-2 therapy demonstrated the establishment of a potent T cell memory response. Furthermore, PD-1–laIL-2 therapy manifested no obvious toxicity. These findings suggest the potential of PD-1–laIL-2 therapy in treating patients with cancer.